Skip to main content
Clinical Trials/NCT03583580
NCT03583580
Active, not recruiting
Not Applicable

A Multicenter Phase Ⅱ Prospective Clinical Trial of Accelerated Partial Breast Irradiation With IMRT After Breast-conserving Surgery in Early Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences1 site in 1 country537 target enrollmentJune 19, 2017

Overview

Phase
Not Applicable
Intervention
Accelerated Partial Breast Irradiation
Conditions
Breast Neoplasms
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Enrollment
537
Locations
1
Primary Endpoint
locoregional control rate
Status
Active, not recruiting
Last Updated
3 months ago

Overview

Brief Summary

This study is to evaluate the efficacy and toxicity of accelerated partial breast irradiation (ABPI) with intensity modulated radiation therapy (IMRT) in low-risk breast cancer treat with breast-conserving surgery.

Detailed Description

This study is a national multicenter phase II prospective clinical trial to enroll low-risk breast cancer treat with breast-conserving surgery. All eligible patients will receive ABPI to a total dose of 40Gy, in 10 fractions, 4Gy/fx/day, within 2 weeks. Intensity modulated radiation therapy (IMRT) technique is used. During Follow up, the locoregional recurrence,survival,acute and late adverse events,and quality of life will be prospectively evaluated.

Registry
clinicaltrials.gov
Start Date
June 19, 2017
End Date
June 1, 2026
Last Updated
3 months ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Shulian Wang

Professor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • Life Expectation: \> 5 years
  • Enrollment date no more than 12 weeks after breast-conserving surgery or no more than 8 weeks after adjuvant chemotherapy
  • Histologically confirmed diagnosis of invasive ductal carcinoma (grade 1-2), or mucinous carcinoma, or papillary carcinoma, or tubular carcinoma, or medullary carcinoma: primary tumor ≤ 3.0cm in maximum diameter and pN0; or histologically confirmed DCIS: primary tumor ≤ 2.5cm in maximum diameter, low-medium grade
  • Unifocal tumour (confirmed by diagnostic MRI)
  • No lymphovascular invasion
  • ER positive (defined as medium-strongly nuclear staining in \>1% of the cancer cells)
  • Negative radial resection margins of \>= 2 mm
  • Surgical clips placed in the tumor bed
  • Written informed consent.

Exclusion Criteria

  • Stage Ⅱ-Ⅲ
  • Multifocal tumors
  • Histologically confirmed diagnosis of invasive ductal carcinoma (grade 3), invasive micropapillary carcinoma, carcinoma of lobular in situ, invasive lobular carcinoma
  • Paget's disease of the nipple
  • Underwent oncoplastic surgery of ipsilateral breast
  • Underwent neoadjuvant chemotherapy or hormonal therapy
  • Previous or simultaneous contralateral breast cancer
  • Undergone ipsilateral chest wall radiotherapy
  • Active collagen vascular disease.

Arms & Interventions

Accelerated Partial Breast Irradiation

Accelerated partial breast irradiation (APBI) to the region of tumour bed

Intervention: Accelerated Partial Breast Irradiation

Outcomes

Primary Outcomes

locoregional control rate

Time Frame: 5 years

ipsilateral breast and axilla nodal relapse rate

Secondary Outcomes

  • distant-metastasis survival(5 years)
  • overall survival(5 years)
  • disease-free survival(5 years)

Study Sites (1)

Loading locations...

Similar Trials